<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45114">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765426</url>
  </required_header>
  <id_info>
    <org_study_id>11-0049</org_study_id>
    <nct_id>NCT01765426</nct_id>
  </id_info>
  <brief_title>Phase 1b Study Investigating Safety &amp; Immunogenicity of DENVax Given Intradermally by Needle or Needle Free PharmaJet Injector</brief_title>
  <official_title>Phase 1b, Partial-Blind, Parallel Group, Randomized Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine (DENVax) Administered Intradermally Using Needle or a Needle-Free PharmaJet® Injector in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inviragen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Inviragen Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory trial to assess the safety, tolerability and immunogenicity of
      vaccination with a tetravalent dengue vaccine in healthy adults delivered intradermally
      using the conventional needle/syringe or a needle-free PharmaJet® injector.  Two (2)
      intradermal injections of either vaccine or placebo will be administered to qualified
      subjects (one in each arm) on Day 0 of the study.  A subsequent injection will also be given
      on Day 90 with either vaccine or placebo (in one arm only).  Subjects will be evaluated for
      safety, measurement of viremia for all four dengue serotypes and dengue neutralizing
      antibody to all four serotypes.  All subjects will be evaluated for injection site
      evaluations and have blood drawn for viremia, neutralizing antibodies, cell mediated
      immunity and innate immunity.  Subjects will be required to participate for approximately 10
      months from recruitment and collection of data for primary outcomes (through Day 120)
      including collection of additional samples for measurement of longer term antibody titers
      (Day 270).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Adverse event frequency</measure>
    <time_frame>120 Days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody titer comparison of the four dengue serotypes</measure>
    <time_frame>270 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure neutralizing antibodies due to each of the four dengue vaccine components after each vaccination</measure>
    <time_frame>270 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety following ID administration of DENVax using the PharmaJet® needle-free injector</measure>
    <time_frame>120 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure viremia due to each of the four dengue vaccine components</measure>
    <time_frame>104 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Normal Healthy Adult</condition>
  <arm_group>
    <arm_group_label>ID DENVax using needle-less PharmaJet injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DENVax Vaccine- low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID DENVax using neele-less PharmaJet injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DENVax Vaccine - low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID DENVax using needle/syringe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DENVax Vaccine - low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID DENVax using needle-free PharmaJet injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DENVax Vaccine - low dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DENVax</intervention_name>
    <description>low dose given intradermally</description>
    <arm_group_label>ID DENVax using needle-less PharmaJet injector</arm_group_label>
    <arm_group_label>ID DENVax using neele-less PharmaJet injector</arm_group_label>
    <arm_group_label>ID DENVax using needle/syringe</arm_group_label>
    <arm_group_label>ID DENVax using needle-free PharmaJet injector</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PharmaJet Injector</intervention_name>
    <arm_group_label>ID DENVax using needle-less PharmaJet injector</arm_group_label>
    <arm_group_label>ID DENVax using neele-less PharmaJet injector</arm_group_label>
    <arm_group_label>ID DENVax using needle-free PharmaJet injector</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health as determined by medical history, physical examination and laboratory
             tests

          -  Negative for HIV, Hepatitis B &amp; C

          -  Body Mass Index (BMI) ≤ 35 kg/m2

        Exclusion Criteria:

          -  Any Grade 2 or above abnormality in the screening laboratory tests

          -  History of Dengue fever, Japanese encephalitis, West Nile or Yellow Fever disease

          -  Seropositivity to dengue or West Nile virus

          -  Extensive scarring or tattoo (&gt; 50%) on arms, shoulders, neck face and head

          -  History of significant dermatologic disease in the last 6 months

          -  Receipt or planned receipt of any vaccine in the 4 weeks preceding or following the
             vaccinations

          -  Any planned travel to dengue endemic areas  including the Caribbean, Mexico, Central
             America, South America or Southeast Asia, during the study period and during the
             month prior to screening

          -  Use of systemic corticosteroids therapy within the previous 6 months (at a dose of
             0.5 mg/kg/day). Topical prednisone is not permitted if currently in use or used
             within the last month.

          -  Use of any prescription or over the counter medication that has not been stable for
             30 days

          -  Planned donation of blood during the period of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilad Gordon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inviragen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>December 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
